NYSE · JNJ

Johnson & Johnson

$265.95 +$2.55 (+0.97%) 1D After hours
Session Pulse Overnight session chatter is louder than usual 2 mentions today · 2 bullish / 0 bearish tags No new SEC filings since Tue close its sector ranked 5/11 this week Full pulse →
Charting by TradingView

Key Metrics

$634.77B
Market cap
30.17×
P/E · TTM
$96.36B
Revenue · TTM
$21.04B
Net income
EPS · TTM $8.68
Dividend yield —
Free cash flow $17.78B
Beta · 1Y -0.16
EBITDA · TTM $32.68B
Gross margin 67.8%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    A material event was filed (Form 8-K).

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 27
    Chatter ran much louder than usual.

    3 mentions across the stream that day (+2.3σ vs its own baseline) — attention, not direction. Loud days mark where the crowd was looking.

    RECEIPT: NARRATIVE VELOCITY, 30-DAY BASELINE
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$634.77B
Enterprise value$650.24B
Shares outstanding2.4B
52-wk range$164.23 – $269.43
Avg volume · 20D8.3M
Net cash −$15.48B
Book value / share$33.50
IndustryPharmaceutical Preparations
ExchangeNYSE
About Johnson & Johnson
IPO dateSep 25, 1944
Employees140800

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E30.17
P/S6.59
P/FCF35.69
EV/EBITDA19.90
EV/Sales6.75
Graham №$80.88

Profitability

Gross 67.8%
Operating 25.9%
Net 21.8%
FCF 18.5%
ROE / ROIC 27.6% · 21.8%

Financial Health

Current ratio1.03
Quick ratio0.77
Debt / equity0.46
Debt / EBITDA 1.15
Net cash −$15.48B
Working capital$1.46B

Cash Flow · TTM

Operating CF $22.87B
Capex −$5.09B
Free cash flow $17.78B
Buybacks $7.85B
Dividends paid —
Shareholder yield 1.2%

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

5.3
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$80.88 vs $265.95
Trades 3.3× above classic defensive value — priced for growth
Fundamentals through 2026-03-29 · computed by TickerWolf from SEC filings